Drugdiscovery >> Drugs >> News
3550
Views
title
New Therapy for ANCA-associated Vasculitis? - drugdiscovery.com


Researchers demonstrated that rituximab is as effective as cyclophosphamide - the current standard of care in patients with ANCA-associated Vasculitis, but has a shorter and simpler treatment course and thus is less toxic.
Read More >>


Tags: ANCA-associated Vasculitis, Rituximab, Rituxan - August 4, 2013
Related Articles
3872
Views
NICE recommends MabThera for the treatment of a rare form of  vasculitis NICE recommends MabThera for the treatment of a rare form of vasculitis
UK’s NICE has given the recommendation for Roche's MabThera, to be used for the treatment of a rare autoimmune disorder called anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Read More >>

Tags: MabThera, ANCA associated vasculitis, Roche, UK

6060
Views
Breakthrough Therapy Designation for Firdapse Breakthrough Therapy Designation for Firdapse
FDA has granted a Breakthrough Therapy Designation to Catalyst Pharmaceutical Partners for the drug Firdapse (amifampridine phosphate), for the symptomatic treatment of patients with Lambert-Eaton Mya Read More >>

Tags: Firdapse, Lambert-Eaton Myasthenic Syndrome, LEMS, orphan drug, breakthrough therapy

5238
Views
Two-drug therapy more effective than Enbrel monotherapy in RA Two-drug therapy more effective than Enbrel monotherapy in RA
According to a latest clinical trial, combined therapy of Enbrel (etanercept) and methotrexate in patients with rheumatoid arthritis (RA) is more effective than monotherapy with Enbrel. Read More >>

Tags: enbrel, etanercept, methotrexate, rheumatoid artritis, RA, monotherapy, two-drug therapy, clinical trial

3341
Views
Breakthrough Therapy designation for AML drug volasertib Breakthrough Therapy designation for AML drug volasertib
The FDA has granted Breakthrough Therapy designation to Boehringer Ingelheim’s investigational compound - volasertib, for the treatment of patients with acute myeloid leukemia. Read More >>

Tags: volasertib, acute myeloid leukemia, Boehringer Ingelheim, breakthrough therapy,experimental drug

5539
Views
Breakthrough Therapy designation for leukemia drug Arzerra Breakthrough Therapy designation for leukemia drug Arzerra
The FDA has granted Breakthrough Therapy designation for the drug Arzerra (ofatumumab), co-development by Genamb and GSK, used in combination with chlorambucil for the treatment of patients with chro Read More >>

Tags: Arzerra, ofatumumab, chronic lymphocytic leukemia, CLL, breakthrough therapy designation

6157
Views
Orphan Drug Designation for ReN003 retinal stem cell therapy Orphan Drug Designation for ReN003 retinal stem cell therapy
ReNeuron Group’s ReN003 retinal stem cell therapy, candidate for retinitis pigmentosa, has been granted Orphan Drug Designation in both Europe and the U.S. Read More >>

Tags: Orphan Drug Designation, ReN003, retinal stem cell therapy, retinitis pigmentosa, orphan drug, stem cell therapy

16242
Views
Breakthrough therapy designation for Roche’s lung cancer drug alectinib Breakthrough therapy designation for Roche’s lung cancer drug alectinib
The FDA has granted breakthrough therapy designation for Roche’s promising investigational 2nd generation ALK inhibitor, used for the treatment of patients with metastatic non-small cell lung cance Read More >>

Tags: alectinib, lung cancer, breakthrough therapy designation, Roche, investigational drug, ALK inhibitor, metastatic non-small cell lung cancer, NSCLC, FDA

5131
Views
Long-term calcium-channel blocker therapy linked to increased breast cancer risk Long-term calcium-channel blocker therapy linked to increased breast cancer risk
A case-control study showed that the risk of breast cancer more than doubled in postmenopausal women who were on a long-term calcium- channel blocker therapy. Women who were on other types of heart dr Read More >>

Tags: calcium-channel blocker,long-term therapy, breast cancer, diuretics, beta-blockers, ACE inhibitors, or angiotensin receptor blockers

4765
Views
Preventive Isoniazid therapy beneficial for HIV-infected people Preventive Isoniazid therapy beneficial for HIV-infected people
A large international study revealed that preventive antibiotic therapy in people with HIV lowers their risk of developing tuberculosis and dying of it. Read More >>

Tags: HIV, Isoniazid, tuberculosis, risk, antibiotic

825
Views
Where you born in the 1960's? Your peers might need a theraphy Where you born in the 1960's? Your peers might need a theraphy
Statistics show that children of the 1960's are more likely to get hospitalized due to being boozed. People of this age might need a therapy, more often than others. Read More >>

Tags: therapy, age, 1960

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013